keyword
MENU ▼
Read by QxMD icon Read
search

Mirvaso

keyword
https://www.readbyqxmd.com/read/27692690/-allergic-contact-dermatitis-to-mirvaso-%C3%A2-brimonidine-tartrate
#1
J-L Schmutz
No abstract text is available yet for this article.
September 28, 2016: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/27272086/paradoxical-erythema-reaction-of-long-term-topical-brimonidine-gel-for-the-treatment-of-facial-erythema-of-rosacea
#2
Erin Lowe, Scott Lim
In 2013 brimonidine tartrate gel 0.33% (Mirvaso Gel, Galderma Laboratories, LP, Fort Worth, TX) was approved by the US Food and Drug Administration for the treatment of facial erythema of rosacea. It is the first and only drug on the market to address the hallmark redness of this chronic, inflammatory disease. Commonly reported adverse events include erythema/flushing worse than at baseline, most often occurring with the first application. We report a unique case of facial erythema of rosacea that responded to brimonidine gel with effective blanching for two years until the patient developed a paradoxical erythema reaction...
June 1, 2016: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/27133629/sensitization-to-and-allergic-contact-dermatitis-caused-by-mirvaso-%C3%A2-brimonidine-tartrate-for-treatment-of-rosacea-2-cases
#3
Nannie Bangsgaard, Louise A N Fischer, Claus Zachariae
No abstract text is available yet for this article.
June 2016: Contact Dermatitis
https://www.readbyqxmd.com/read/26768997/allergic-contact-dermatitis-caused-by-mirvaso%C3%A2-brimonidine-tartrate-gel-0-33-a-new-topical-treatment-for-rosaceal-erythema
#4
Hannah Cookson, John McFadden, Jonathan White, Ian R White
No abstract text is available yet for this article.
December 2015: Contact Dermatitis
https://www.readbyqxmd.com/read/26714888/facial-erythema-of-rosacea-aetiology-different-pathophysiologies-and-treatment-options
#5
Martin Steinhoff, Martin Schmelz, Jürgen Schauber
Rosacea is a common chronic skin condition that displays a broad diversity of clinical manifestations. Although the pathophysiological mechanisms of the four subtypes are not completely elucidated, the key elements often present are augmented immune responses of the innate and adaptive immune system, and neurovascular dysregulation. The most common primary feature of all cutaneous subtypes of rosacea is transient or persistent facial erythema. Perilesional erythema of papules or pustules is based on the sustained vasodilation and plasma extravasation induced by the inflammatory infiltrates...
June 15, 2016: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/26466509/-brimonidine-mirvaso-dermal-use
#6
Dana Van Genechten
No abstract text is available yet for this article.
June 2015: Journal de Pharmacie de Belgique
https://www.readbyqxmd.com/read/25505014/brimonidine-for-erythema-caused-by-rosacea
#7
REVIEW
(no author information available yet)
Brimonidine gel (Mirvaso-Galderma) became available in February of this year for the symptomatic treatment of facial erythema associated with rosacea in adults.1 Here, we review the evidence on brimonidine gel and consider its place in the management of erythema associated with rosacea.
December 2014: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/25151933/-erythema-of-rosacea-a-new-and-effective-treatment
#8
MULTICENTER STUDY
F G Hougeir
Until recently, our rosacea patients have had to suffer of their erythema with limited effective treatments. Mirvaso(®) (Brimonidine tartrate 0.5%, Brimonidine 3mg/g) is a new medication, indicated for the treatment of the erythema of rosacea. The phase III pivotal and long term studies showing the efficacy and tolerability of Mirvaso(®) are summarized.
September 2014: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/25007365/optical-coherence-tomography-imaging-of-erythematotelangiectatic-rosacea-during-treatment-with-brimonidine-topical-gel-0-33-a-potential-method-for-treatment-outcome-assessment
#9
Jennifer Urban, Arunee H Siripunvarapon, Adam Meekings, Amy Kalowitz, Orit Markowitz
BACKGROUND: Patients with moderate to severe rosacea often seek treatment to reduce erythema and vascular markings. Few studies have looked at the effectiveness of the novel treatment, brimonidine topical gel 0.33%, trademark name Mirvaso®, in the treatment of rosacea. We report the use of optical coherence tomography (OCT) scanning to monitor the effectiveness of Mirvaso® on in vivo skin. OCT is a non-invasive optical imaging technique that can provide high-resolution imaging of vessel and cellular morphology...
July 2014: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/24720083/mirvaso-brimonidine-tartrate-topical-gel-0-33
#10
William Abramovits, Ana Prato, Kimberly D Vincent, Noah Scheinfeld, Aditya K Gupta
No abstract text is available yet for this article.
January 2014: Skinmed
https://www.readbyqxmd.com/read/24129112/brimonidine-gel-mirvaso-for-rosacea
#11
(no author information available yet)
No abstract text is available yet for this article.
October 14, 2013: Medical Letter on Drugs and Therapeutics
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"